ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator - Trial NCT03198507
Access comprehensive clinical trial information for NCT03198507 through Pure Global AI's free database. This Phase 3 trial is sponsored by RedHill Biopharma Limited and is currently Completed. The study focuses on Helicobacter Pylori Infection,Dyspepsia. Target enrollment is 455 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
RedHill Biopharma Limited
Timeline & Enrollment
Phase 3
Jun 18, 2017
Dec 13, 2018
Primary Outcome
Number of Participants With Eradication of H. Pylori
Summary
The test and treat strategy for treating dyspeptic patients who are H. pylori positive is
 rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a
 new triple therapy to treat H. pylori infection in dyspeptic patients against an active
 comparator.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03198507
Non-Device Trial